Business Wire

Western Union Collaborates with Leading French Fintech Linxo to Launch Digital Money Transfers

Share

Western Union, a leader in cross-border, cross-currency money movement and payments, has collaborated with Linxo, a leading budget management and bank account aggregation application in France, to enable users to make local and cross-border payments through Western Union’s platform.

Linxo’s customers can now make and manage money transfers through Western Union’s platform, quickly, conveniently, and reliably, 24/7. Users can fund their transfers through their bank account or card, and have their funds paid out into billions of bank accounts and millions of mobile wallets in approximately 125 countries, or more than half a million retail locations in more than 200 countries and territories.

We are pleased to be joining forces with Linxo, offering the 3.5 million users of this innovative app access to the broadest digital global network coverage within the cross-border person-to-person payment sector,” said Massimiliano Alvisini, Head of Europe, CIS, and Africa Network at Western Union. “In France, and across the world, we partner with fintechs, banks and post offices, offering their customers flexibility and trust underpinned by technology, customer experience and compliance,” he said.

Established in 2010, Linxo is a pioneering account aggregation fintech, that optimizes bank account and transaction management for its users. The Linxo application is available in both free and premium versions on the Apple App Store and on Google Play.

By integrating the Western Union platform into our Linxo Marketplace, we are providing our users with a new and seamless customer experience thanks to enhanced functionalities for themanagement of their financial assets from a single space: consultation and management of accounts, sending or transferring money to their families and loved ones,” comments Bruno Van Haetsdaele, CEO and Co-Founder of Linxo Group. “Our ambition was to create a virtuous and open ecosystem. With the integration of the Western Union platform, this is now a reality. And we will continue to integrate new value-added services to provide our users with a quality service that exceeds their expectations within the Linxo application.”

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Western Union’s platform provides seamless cross-border flows, and its leading global financial network bridges more than 200 countries and territories and over 130 currencies. We connect businesses, financial institutions, governments, and consumers through one of the world’s widest reaching networks, accessing billions of bank accounts, millions of digital wallets and cards, and over half a million-retail locations. Western Union connects the world to bring boundless possibilities within reach. For more information, visit www.westernunion.com

About Linxo

Linxo Group is a subsidiary of Crédit Agricole Payment Services, which {harnesses} Crédit Agricole Group’s expertise in marketing, innovation, processing and interbank representation. Since 2010, Linxo Group has been developing and marketing solutions for account aggregation, payment initiation and personal finance management.

The platform of its subsidiary Oxlin, a payment institution authorised by the ACPR [French Prudential Supervision and Resolution Authority], provides all the technology to access banking data and initiate transfers (services regulated by the Revised European Payment Services Directive no. 2, known as PSD2), with the customer's consent and in a totally secure manner.

The services it offers range from API (Application Program Interface) bricks to complete white-label mobile app solutions covering the needs of start-ups as well as banks and insurance companies. These solutions enable the development of new services and new sources of revenue from multiple use cases: budget management, pathways to credit grants, accounting, loyalty, etc.

Its mobile application Linxo, which is already installed and used by more than 3 million people in France, is an intelligent financial assistant, which allows everyone to have an overview of their finances and to simplify the management of their money.

The company has 85 employees, mainly in Aix-en-Provence and in the Crédit Agricole Villages in Paris and Sophia Antipolis.

WU-G

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contacts:
Nicholas Mandalas
Nicholas.Mandalas@wu.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s ESG Solutions Launches Solution to Help Investors Assess Alignment With UN Global Compact3.8.2021 10:14:00 CEST | Press release

Moody’s ESG Solutions announced today the launch of its Global Compact Screening tool, which allows market participants to evaluate companies’ alignment with the principles set by the United Nations Global Compact (UNGC), the world’s largest corporate sustainability initiative. Sustainable investment is rising both in volume and as a percentage of assets under management (AUM) globally. Amid this growing focus on responsible investing, Moody’s Global Compact Screening tool provides financial institutions with essential data for portfolio and risk management as well as reporting. It helps investors integrate global ESG standards into their portfolio management practices and develop socially responsible investing (SRI- labelled) funds and indices, while allowing asset owners to evaluate the ESG risk exposure of their portfolio holdings. This type of screening is critical for market participants who are increasingly seeking to follow UNGC standards in their sustainability journey, particu

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development3.8.2021 10:00:00 CEST | Press release

In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. The company’s success is based on its rich R&D portfolio with a focus on diseases with high unmet medical need. The R&D pipeline in Human Pharma comprises more than 60 new substances and around 100 clinical and pre-clinical projects. This pipeline has the potential to deliver up to 15 medicines for approval by 2025. In July, Boehringer Ingelheim reported a breakthrough in the treatment of heart failure with empagliflozin (marketed as JARDIANCE®). More than 60 million patients worldwide suffer from this disease, approx. half of them from heart failure with preserved ejection fraction (HFpEF). Heart failure with left ventricular preserved ejection fraction occurs when the left ventricle of the heart is unable to fill properly, resulting in less blood being pumped to the body. A recent trial showed a significantly lower risk with empagliflozin of hospi

Gopher Response to Statement by Playtech, Related Clarifications and Reasons Why Shareholders Should VOTE AGAINST the Consortium Offer3.8.2021 09:09:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Gopher Investments (“Gopher”), a 4.97% shareholder in Playtech plc (“Playtech”), is highly disappointed with the Board of Playtech’s decision not to change its recommendation in relation to the offer from Finalto’s management team backed by a consortium led by Barinboim Group (the “Consortium”). Gopher does not believe the supplementary circular contains a full and fair representation of the interaction between Gopher and Playtech since the previous adjournment of the general meeting and therefore wishes to clarify the following chain of events: Gopher responded promptly to an initial information request from the Board, relating to Gopher’s financing and its high confidence of regulatory approval. The Board sought additional information which was commercially conf

SES Networks Expands Partnership With Orange to Enhance Maritime Services3.8.2021 08:50:00 CEST | Press release

Orange maritime customers will now be able to accelerate their digital transformation with higher-capacity satellite connectivity services provided jointly by SES Networks and Orange. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005841/en/ SES Networks Expands Partnership With Orange to Enhance Maritime Services (Photo: Business Wire) With this innovative agreement, Orange will integrate its own global infrastructure with the global network coverage powered by SES Networks’ Skala Global Platform. Together it will enable Orange maritime customers to cost-effectively scale up their bandwidth with seamless, ubiquitous and global services. This will ensure they can implement new technologies onboard that take advantage of IoT and AI, as well as edge and cloud applications. The combination of the Orange secured and digital network infrastructure and SES Networks’ Skala Global Platform -- a next-generation technology platf

Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis3.8.2021 07:03:00 CEST | Press release

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that, via its newly acquired subsidiary, AdVita Lifescience GmbH, the Company has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis. RLF-100 is a synthetic form of vasoactive intestinal peptide. In open label exploratory clinical experience in sarcoidosis patients, RLF-100 has been shown to be well tolerated and safe, and to produce favorable immunoregulatory effects in the lungs that have been associated with symptom relief in a significant proportion of the patients. “Receipt of our third Orphan Drug Designation is another important milestone for the Company, as it underscores the potential strength of our pipeline and the high need for be

Smart Engages P.I. Works for Expanded Network Automation Solution3.8.2021 07:00:00 CEST | Press release

Smart Communications, Inc. (Smart), the wireless unit of the Philippines’ largest, fully integrated telecommunications company PLDT, has partnered with P.I. Works for a comprehensive strategy for its Self-Organizing Network (SON) Solution to automate its multi-vendor, multi-technology networks. A self-organizing network (SON) is an automation technology designed to make the planning, configuration, performance management, coverage and quality optimization and healing of mobile radio access networks efficient, simpler and faster. This automation is expected to significantly improve the performancemanagement and service quality enhancements of the Smart wireless network, which will result in an improved experience for Smart customers across the country. Under its Network Operations Transformation program, Smart started working with P.I. Works in 2018 through another entity, to enable Artificial Intelligence (AI) and Machine Learning (ML) technologies for the automation of various network

Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients2.8.2021 22:05:00 CEST | Press release

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,"(1) in Clinical Cancer Research, a journal published by the American Association for Cancer Research. The study details the development of the Personalis Neoantigen Presentation Score (NEOPS™), a novel composite biomarker for predicting response to cancer immunotherapy. Enabled by comprehensive tumor immunogenomic profiling from the Personalis NeXT Platform, NEOPS simultaneously models both neoantigen burden and immune-related resistance mechanisms to better predict immunotherapy response in a cohort of late-stage melanoma patients. In this study, NEOPS was more strongly predictive of therapy response than other standard single analyte and investigational biomarkers tested, including tumor mutational b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom